FDA Approves Liquid Biopsy Companion Diagnostic for Wilserdly Breast Cancer Therapy
The CDx is the first approved test to identify patients with ESR1-mutated advanced breast cancer who may be eligible for the treatment.
The CDx is the first approved test to identify patients with ESR1-mutated advanced breast cancer who may be eligible for the treatment.
Studies presented at the Association for Molecular Pathology annual meeting evaluate how artificial intelligence can support diagnosis, reporting, and genetic test selection.
CDC surveillance data show influenza activity higher than typical for early November, with Washington state public health laboratories confirming two new H5 infections.
Researchers identified an RNA biomarker that detected precancerous fallopian tube lesions with 92.3% sensitivity and 98.2% specificity in a validation cohort.
The molecular panels feature changes to norovirus and Campylobacter detection intended to improve specificity, with results available in about one hour.
Contrario Medical's single-use device uses a two-membrane design to prepare motile sperm from semen samples.
The molecular test could help identify patients more likely to respond to abatacept, with early access expected in 2027.
Researchers developed a simplified metabolic health score using routine blood markers to identify people at greater risk of developing cardiometabolic disease.
The patent expands intellectual property coverage for the blood-based assay ahead of its planned commercial launch.
In a study of 229 patients, an AI-based liquid biopsy matched magnetic resonance elastography in identifying patients with fibrosis stages associated with eligibility for approved MASH treatments.
A study of more than 1,100 transplant recipients found that persistent or later-emerging elevations in donor-derived cell-free DNA were associated with greater risks of rejection and graft loss.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
Tampa General Hospital is the first in the Southeast to implement the MeMed BV host-response test in its emergency workflow, reporting a 33% reduction in cefepime use and 13% fewer hospitalizations, according to hospital-led research.